8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Expression of α-AR Subtypes in T Lymphocytes and Role of the α-ARs in Mediating Modulation of T Cell Function

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives: Previous work in our laboratory has shown that α-adrenoreceptors (α-ARs) and β-ARs exist on lymphocytes from functional profile, and that the receptors mediate the regulation of lymphocyte function by catecholamines. In the present study, we directly examined the expression of α-AR subtypes, α<sub>1</sub>-AR and α<sub>2</sub>-AR mRNAs, in T lymphocytes and explored the roles of the α-AR subtypes and intracellular signal transduction mechanisms linked to the receptors in mediating the modulation of T lymphocyte function. Methods: T lymphocytes from mesenteric lymph nodes of rats were purified by using a nylon wool column. Reverse transcription polymerase chain reaction was used to detect the expression of α<sub>1</sub>-AR and α<sub>2</sub>-AR mRNAs in the freshly isolated T cells and the mitogen concanavalin A (Con A)-activated lymphocytes. Colorimetric methylthiazoletetrazolium assay was employed to measure lymphocyte proliferation induced by Con A. Interferon-γ (IFN-γ) and interleukin-4 (IL-4) levels in the Con A-stimulated lymphocyte culture supernatants were examined by enzyme-linked immunosorbent assay. Results: T cells expressed both α<sub>1</sub>-AR and α<sub>2</sub>-AR mRNAs. The expression of both α<sub>1</sub>-AR and α<sub>2</sub>-AR mRNAs was significantly higher in the Con A-activated lymphocytes than in the resting lymphocytes. Phenylephrine, a selective α<sub>1</sub>-AR agonist, had no evident effect on lymphocyte proliferation nor on IFN-γ and IL-4 production induced by Con A. However, the selective α<sub>2</sub>-AR agonist clonidine attenuated Con A-induced lymphocyte proliferation as well as IFN-γ and IL-4 production. The inhibited lymphocyte proliferation and IFN-γ and IL-4 production by clonidine were blocked by yohimbine, an α<sub>2</sub>-AR antagonist. Either phospholipase C inhibitor U-73122 or protein kinase C inhibitor chelerythrine partially prevented the suppressive effect of clonidine on Con A-stimulated lymphocyte proliferation and IL-4 production. Conclusions: T lymphocytes express both α<sub>1</sub>-ARs and α<sub>2</sub>-ARs, but only the α<sub>2</sub>-ARs participate in the suppressive modulation of lymphocyte proliferation and cytokine production in vitro. The inhibitory effect of α<sub>2</sub>-AR stimulation on lymphocyte function is partially mediated via the phospholipase C-protein kinase C pathway.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          The role of phosphoinositide 3-kinase lipid products in cell function.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Instructive Role of Innate Immunity in the Acquired Immune Response

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells.

              Although the beta2-adrenergic receptor (beta2AR) is the most extensively characterized G-protein-coupled receptor (GPCR), the effects of beta-agonists on T-cell subtype function remain poorly understood. In contrast to studies suggesting lack of beta2AR expression on type 2 T cells, we demonstrate that type 2 interleukin-13+ (IL-13+) T cells (CD4+ or CD8+) in human peripheral blood lymphocytes (PBLs) can respond directly to beta-agonist, with effects including induction of protein kinase A (PKA) activity and associated inhibition of CD3-stimulated CD25 expression; CD3-stimulated IL-13, interferon-gamma (IFN-gamma), and IL-2 production; and p38 mitogen-activated protein kinase (MAPK) phosphorylation. PGE2 was more efficacious than beta-agonist in activating PKA and inhibiting cytokine production. beta-agonist and PGE2 also inhibited phorbol myristate acetate (PMA) + calcimycin-stimulated IFN-gamma and IL-2 (but not IL-13) production, suggesting that upstream CD3-initiated signaling is not the sole locus of PKA actions. Differential regulation of PMA-stimulated p38, p42/p44, and NF-kappaB explained the capacity of PGE2 and beta-agonist to inhibit IFN-gamma but not IL-13 production. The inhibition of CD3 + CD28-stimulated IL-13 production by both beta-agonist and PGE2 was reversed at low agonist concentrations, resulting in enhanced IL-13, but not IFN-gamma or IL-2, production. These findings identify direct effects of beta2AR activation on T-cell subtypes and suggest a complex role for GPCRs and PKA activity in modulating T-cell functions.
                Bookmark

                Author and article information

                Journal
                NIM
                Neuroimmunomodulation
                10.1159/issn.1021-7401
                Neuroimmunomodulation
                S. Karger AG
                1021-7401
                1423-0216
                2007
                May 2008
                07 May 2008
                : 14
                : 6
                : 344-353
                Affiliations
                Department of Physiology, School of Medicine and Key Laboratory of Neuroregeneration of Jiangsu Province, Nantong University, Nantong, China
                Article
                129670 Neuroimmunomodulation 2007;14:344–353
                10.1159/000129670
                18463421
                8b947cbc-d32a-4cdd-8be7-5e41c4a87e9c
                © 2008 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 10 October 2007
                : 22 February 2008
                Page count
                Figures: 4, References: 46, Pages: 10
                Categories
                Original Paper

                Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
                T lymphocytes,Phospholipase C,Protein kinase C,α2-Adrenoreceptors,Interferon-γ,Interleukin-4,Clonidine,Yohimbine

                Comments

                Comment on this article